Recursion PharmaceuticalsRXRX
RXRX
0
Funds holding %
of 7,390 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
163% more first-time investments, than exits
New positions opened: 84 | Existing positions closed: 32
97% more repeat investments, than reductions
Existing positions increased: 116 | Existing positions reduced: 59
67% more funds holding in top 10
Funds holding in top 10: 6 [Q3] → 10 (+4) [Q4]
19% more capital invested
Capital invested by funds: $1.73B [Q3] → $2.06B (+$333M) [Q4]
18% more funds holding
Funds holding: 264 [Q3] → 312 (+48) [Q4]
1% less call options, than puts
Call options by funds: $30.7M | Put options by funds: $30.9M
13.93% less ownership
Funds ownership: 93.35% [Q3] → 79.42% (-13.93%) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$6
3%
upside
Avg. target
$9
55%
upside
High target
$11
89%
upside
3 analyst ratings
2 positive
67%
1 neutral
33%
0 negative
0%
Leerink Partners Mani Foroohar 33% 1-year accuracy 5 / 15 met price target | 3%upside $6 | Market Perform Maintained | 28 Feb 2025 |
Needham Gil Blum 9% 1-year accuracy 15 / 160 met price target | 89%upside $11 | Buy Reiterated | 6 Feb 2025 |
Keybanc Scott Schoenhaus 29% 1-year accuracy 9 / 31 met price target | 72%upside $10 | Overweight Maintained | 8 Jan 2025 |
Financial journalist opinion
Based on 10 articles about RXRX published over the past 30 days
Positive
The Motley Fool
18 hours ago
Should Investors Buy These 2 Beaten-Down Artificial Intelligence (AI) Healthcare Stocks?
Artificial intelligence (AI) is changing the world. Corporations are racing to establish themselves as leaders in the field, while investors want to cash in by putting their hard-earned money into the most promising AI companies.
Positive
The Motley Fool
23 hours ago
Nvidia Has 81% of Its $304 Million Stock Portfolio Invested in 3 Groundbreaking AI Stocks
The semiconductor giant Nvidia (NVDA -1.51%) is quite the company, developing high-end graphics processing units (GPUs) that help power artificial intelligence (AI) applications. Many investors view Nvidia as the picks-and-shovels play for AI, which would be pretty remarkable given how much AI is expected to change nearly all aspects of our daily lives.
Neutral
Zacks Investment Research
1 week ago
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today
In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $6.48, denoting a -1.52% change from the preceding trading day.
Neutral
Zacks Investment Research
1 week ago
Recursion Pharma Down 37% in a Month: Buy, Sell or Hold the Stock?
Despite the current downward trend of RXRX, one should retain the stock for long-term gains due to the significant potential of its AI-driven drug discovery technology.
Negative
The Motley Fool
2 weeks ago
Why Recursion Pharmaceuticals Stock Is Sinking Today
Shares of Recursion Pharmaceuticals (RXRX -5.54%) were sinking 8.2% lower as of 10:57 a.m. ET on Monday.
Positive
The Motley Fool
3 weeks ago
Is This Beaten-Down Artificial Intelligence (AI) Stock a Buy?
The artificial intelligence (AI) industry has been on a tear in the past two years, and judging by analyst estimates, it's just the beginning. AI-related sales will continue to soar in the coming years, so naturally, investors want to cash in by investing in those companies best positioned to profit from AI.
Positive
The Motley Fool
3 weeks ago
4 Things You Need to Know if You Buy Recursion Pharmaceuticals Stock Today
Investors looking for an exciting clinical-stage biotech start-up with enormous potential should be paying close attention to Recursion Pharmaceuticals (RXRX -5.17%).
Neutral
The Motley Fool
3 weeks ago
This Biotech Stock Could Be the Best Investment of the Decade
It's typically not too difficult to find a company that should perform well for the next couple of years. Two years isn't very long, after all, and the stock market's dynamics tend to dictate performance more.
Positive
The Motley Fool
3 weeks ago
Down Over 40%, Is Recursion Pharmaceuticals a Buy on the Dip?
Machine-learning techniques keep improving efficiency in one industry after another. One corner of the economy where investors expect another big leap forward is the world of drug development.
Positive
Benzinga
3 weeks ago
Recursion Pharmaceuticals' Update Could Shed Light On Pipeline, Cost-Saving Plans, Analyst Says
Recursion Pharmaceuticals Inc RXRX is a leader in the TechBio space "due to its broad capabilities and extensive internal data generation," according to Needham.
Charts implemented using Lightweight Charts™